Scientists have discovered a protein that plays a central role in promoting immunity to viruses and cancer, opening the door to new therapies.
Experiments in mice and human cells have shown that the protein promotes the proliferation of cytotoxic T cells, which kill cancer cells and cells infected with viruses. The discovery was unexpected because the new protein had no known function and doesn’t resemble any other protein.
Researchers from Imperial College London who led the study are now developing a gene therapy designed to boost the infection-fighting cells, and hope to begin human trials in three years.
The study also involved researchers at Queen Mary University of London, ETH Zurich and Harvard Medical School. Their discovery, which has been six years in the making, is reported today in the journal Science.
Cytotoxic T cells are an important component of the immune system, but when faced with serious infections or advanced cancer, they are often unable to proliferate in large enough quantities to fight the disease.
By screening mice with genetic mutations, the Imperial team discovered a strain of mice that produced 10 times as many cytotoxic T cells when infected with a virus compared with normal mice. These mice suppressed the infection more effectively, and were more resistant to cancer. They also produced more of a second type of T cells, memory cells, enabling them to recognise infections they have encountered previously and launch a rapid response.
The mice with enhanced immunity produced high levels of a hitherto unknown protein, which the researchers named lymphocyte expansion molecule, or LEM. They went on to show that LEM modulates the proliferation of human T cells as well as in mice.
The researchers now aim to develop a gene therapy designed to improve immunity by boosting the production of LEM. With the support of Imperial Innovations, the technology commercialisation company for the College, the researchers have filed two patents. A company called ImmunarT has been formed with the aim of commercialising the technology.
Professor Philip Ashton-Rickardt from the Section of Immunobiology in the Department of Medicine at Imperial, who led the study, said: “Cancer cells have ways to suppress T cell activity, helping them to escape the immune system. Genetically engineering T cells to augment their ability to fight cancer has been a goal for some time and techniques for modifying them already exist. By introducing an active version of the LEM gene into the T cells of cancer patients, we hope we can provide a robust treatment for patients.
“Next we will test the therapy in mice, make sure it is safe and see if it can be combined with other therapies. If all goes well, we hope to be ready to carry out human trials in about three years.”
The Latest on: Cytotoxic T cell
via Google News
The Latest on: Cytotoxic T cell
- Pharmacovigilance Needed for Immune Checkpoint Inhibitor Therapy in NSCLCon September 6, 2019 at 7:31 am
In recent years, immune checkpoint inhibitors (ICIs), such as anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) and antiprogrammed death-1 (PD-1) therapies have been found to improve survival rates among ...
- TAMpering with TIMEon September 4, 2019 at 12:15 pm
The human immune system is naturally antitumor, and the premise of immune checkpoint blockade in cancer therapy is to relieve the constraints on cytotoxic T lymphocytes so they can kill tumor cells.
- Global CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market 2019-2023 | Growing Popularity of Combination Therapy to Boost Growth | Ton September 4, 2019 at 3:00 am
LONDON--(BUSINESS WIRE)--#Biotechnology--The global CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 ... proteins that restrict the action of the immune system that prevents T-cells from eliminating ...
- OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Paon September 3, 2019 at 9:00 am
The research program is conducted by physician-scientist Prasad S. Adusumilli, M.D., FACS, an expert in tumor immunology with a focus on the development of chimeric antigen receptor T-cell (CAR T-cell ...
- Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1on August 29, 2019 at 8:26 am
We demonstrate that breast carcinoma cells exposed to radiation shed TMPs containing elevated levels of immune-modulating proteins, one of which is programmed death-ligand 1 (PD-L1). These TMPs ...
- AbbVie axes multi-billion cancer flop Rova-T after another trial failson August 29, 2019 at 7:37 am
The idea behind Rova-T is to use the antibody to target ... prevalent in tumour cells and cancer stem cells but not healthy tissue. Then the cytotoxic agent tesirine could be delivered directly ...
- Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelinationon August 29, 2019 at 2:20 am
In vitro, OPCs exposed to IFNγ cross-present antigen to cytotoxic CD8 T cells, resulting in OPC death. In human demyelinated MS brain lesions, but not normal appearing white matter, oligodendroglia ...
- Management of Steroid-Refractory Immune-Related Adverse Eventson August 27, 2019 at 2:38 am
The only US Food and Drug Administration (FDA)-approved ICIs include cytotoxic T-lymphocyte–associated antigen ... immune checkpoint inhibition can lead to activation of autoreactive T-cells resulting ...
- Creative Biolabs Offers Versatile Bispecific Antibodies for Various Applicationson August 26, 2019 at 7:55 am
redirecting cytotoxic immune cells, or delivering radioactive therapeutics, most of which act through T cell recruitment and NK cell recruitment, designed to bind tumor-associated antigens and CD3 or ...
- New evidence shows cytotoxic T cells can identify, invade, and destroy targets of large mass like T. gondii tissue cystson July 10, 2019 at 12:38 am
CD8+ cytotoxic T lymphocytes can kill host cells infected with various microorganisms as well as single individual cancer cells through direct cell-to-cell contact, but their ability to destroy a ...
via Bing News